Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets

Published - Sep 2016| Code - PHM119B| Publisher - BCC Publishing

Report Highlights

The global market for antithrombotic/anticoagulant drugs should reach $27.3 billion by 2021 from $18.9 billion in 2016 at a compound annual growth rate (CAGR) of 7.6%, from 2016 to 2021.

Report Includes

  • An overview of the global market for antithrombotic/anticoagulant drugs, which is changing due to factors such as an aging population, an increase in thrombotic events, and recent advances in pharmaceuticals
  • Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021
  • Breakdowns of the market size of anticoagulants by revenue at manufacturers' sales levels, including low molecular weight heparins and oral anticoagulants, as well as breakdowns of antiplatelets and thrombin inhibitors
  • Discussion of research and development of antithrombotic/anticoagulant treatments
  • Profiles of top leaders in each of the market segments along with companies that are novel or have specific interest to the field

Report Scope

This report is a comprehensive business tool designed to provide an in-depth look at antithrombotic/anticoagulant drugs for various cardiovascular applications. The geographic scope of the report is global, with a special emphasis on individual regions such as the United States, Europe, Asia-Pacific and the rest of world. The report describes the industry, its relationship to the healthcare industry and its participants and future trends.

Categories discussed in the report include:

  • Anticoagulants.
  • Antiplatelets.
  • Thrombin inhibitors.

All categories are discussed in detail, describing each segment, identifying current products on the market, measuring market size, identifying market drivers, forecasting for 2016 to 2021 and assessing the competitors their market shares.

Analyst Credentials

ANUJ PATHAK has written and researched the global medical device market, surgical instruments and biotechnology market. Skilled in information technology and computer management, he has an undergraduate business degree and an MBA degree.

Latest reports include:

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter Name Pages Price Member Price
Full Report: Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets 156 $2,750 Free
Chapter- 1: Introduction3Free
Chapter- 2: EXECUTIVE SUMMARY3$250Free
Chapter- 3: INDUSTRY OVERVIEW36$635Free
Chapter- 4: ANTICOAGULANTS23$405Free
Chapter- 5: ANTIPLATELETS19$335Free
Chapter- 6: THROMBIN INHIBITORS21$370Free
Chapter- 7: COMPANY PROFILES37$652Free
Chapter- 8: APPENDIX A: LIST OF PATENTS8$141Free
Chapter- 9: APPENDIX B: DIRECTORY OF COMPANIES COVERED IN THIS REPORT6$106Free
Published - Jan-2013| Analyst - Mary Anne Crandall| Code - PHM119A

Report Highlights

The global anticoagulant drug market was valued at nearly $5.8 billion in 2011 and should reach nearly $5.7 billion in 2012.  Total market value is expected to reach nearly $5.4 billion in 2017 after decreasing at a five-year compound annual growth rate (CAGR) of -1.1%.

Report Includes

  • An overview of the global market for antithrombotic/anticoagulant drugs, which is changing due to factors such as an aging population, an increase in thrombotic events, and recent advances in pharmaceuticals
  • Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
  • Breakdowns of the market size of anticoagulants by revenue at manufacturers' sales levels, including low molecular weight heparins and oral anticoagulants, as well as breakdowns of antiplatelets and thrombin inhibitors
  • Discussion of research and development of antithrombotic/anticoagulant treatments
  • Comprehensive company profiles of top leaders in each of the market segments along with companies that are novel or have specific interest to the field.
RELATED REPORTS
Share This Report